Overview
Komzifti is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) that carries a susceptible nucleophosmin 1 (NPM1) mutation (gene variation). To be eligible for Komzifti, a person must test positive for the NPM1 genetic mutation and have AML that has not responded to previous treatments or has returned. Komzifti is also known by its drug name, ziftomenib.
Komzifti is a menin inhibitor. It works by blocking a protein that helps leukemia cells grow. This helps the cells develop more normally and may slow down or stop the disease.

How do I take it?
Prescribing information states that Komzifti is taken as an oral capsule once daily. Treatment continues until the disease progresses or side effects become unmanageable. People without disease progression or severe side effects should take Komzifti for at least six months to allow time for a clinical response, according to the prescribing label. The drug should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Komzifti include infections without a known cause, bleeding, diarrhea, nausea, fatigue, edema (swelling), bacterial infections, muscle or bone pain, differentiation syndrome (a potentially life-threatening complication where leukemia cells rapidly mature), pruritus (itching), febrile neutropenia (fever with low white blood cell count), and increased liver enzymes.

Rare but serious side effects may include differentiation syndrome, which can be fatal if not treated promptly. Other serious effects include prolonged QTc interval (a heart rhythm condition that can cause irregular heartbeat), and potential harm to an unborn baby. Electrolyte imbalances such as low potassium or magnesium levels and liver problems may also occur.

For more information about this treatment, visit:

Komzifti (Ziftomenib) Capsules, for Oral Use — Kura Oncology